Medexus Pharmaceuticals Inc MEDXF

The Good outweighs the Bad in YE data

[GoldenArm]

When you read the Q4'21 you'll see that revenues were 800K less than year ago number. This can be a bummer but the real story for this company will be:

Ken d’Entremont, Chief Executive Officer of Medexus, noted, “Fiscal 2021 was another record year for Medexus as we achieved $79.7 million in total revenue, or 43.5% year-over-year revenue growth, and continued to expand our business in the United States. We are optimistic that the licensing of treosulfan in the U.S. will prove to be another transformative transaction that will enable us to continue our growth trajectory. Our goal is to double our revenue in the coming years. As we look to fiscal 2022, treosulfan will be a primary focus for the Company. Feedback from FDA thus far has been very encouraging as we approach the August 11 th Prescription Drug User Fee Act (PDUFA) date. We are expecting seven and a half years of exclusivity as a result of the inclusion of pediatric patients on the label and believe treosulfan has the potential to become standard of care in the United States. This product has excellent revenue potential and we believe it will have a substantially positive impact on our gross margin. To ensure a smooth and effective launch after approval, it is crucial that we invest in a highly experienced team and the proper resources to support the product launch. Our new Medical Affairs team is already engaging thought leaders in the stem cell transplant community and market research is confirming key launch assumptions around demand, pricing, and product positioning.”

[Finallytherock]

the numbers were okay. i expect there to some improvement next quarter. it's all about approval of treosulfan right now. it can more than double revenues for this company. once approved, i expect a quick ramp up in use, couple that with our other products and hopefully new ones coming, things look really good for a company with a $100 million market cap.

[GoldenArm]

Agree. To bad about Nasdaq being dropped. Better for the company because of the cost and going on the Nasdaq. Once Treo is approved and cash is rolling in then they can consider it again.

[Finallytherock]

yeah, i'd like to see them on the nasdaq by the time treo is approved but not sure that will happen. i think being on the nasdaq is important but to be honest, i follow a few companies who just uplisted to the nasdaq and their stock not only dropped but the volume was very low. maybe it's not as of a big deal than we think. for now, treo is of utmost importance. should be approved in less